Trevena announced TRV027 selected for study in global REMAP-CAP trial in COVID-19 patients
On Apr. 21, 2021,Trevena announced that TRV027, the Companyï¾’s novel AT1 receptor selective agonist, had been selected for…
On Apr. 21, 2021,Trevena announced that TRV027, the Companyï¾’s novel AT1 receptor selective agonist, had been selected for…
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
On Apr. 20, 2021, the University of Oxford, Prenetics, and Oxford Suzhou Centre for Advanced Research announced that…
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
On Apr. 20, 2021, LabCorp announced the availability of the Pixel by Labcorpï¾® COVID-19 PCR Test Home Collection…
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
On Apr. 20, 2021, a new collaboration between Roswell Park and the Wilmot Cancer Institute was announced that…
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
On Apr. 19, 2021, Resverlogix announced the publishing of an article titled: モBromodomain and extraterminal protein inhibitor, apabetalone…
On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacï¾’s mRNA-based COVID-19…
On Apr. 19, 2021, Abbott announced it had begun shipping its BinaxNOWï¾™ COVID-19 Ag Self Test to retailers…
On Apr. 19, 2021, researchers at the University of Oxford launched a human challenge trial to look at…
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
On Apr. 19, 2021, the Mayo Clinic announced a study that bolstered evidence that colorectal cancer is often…
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
On Apr. 19, 2021, the NIH announced that it was funding a large, randomized, placebo-controlled Phase 3 clinical…
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
On Apr. 16, 2021, the FDA revoked the emergency use authorization (EUA) that allowed for Eli Lilly’s investigational…
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
On Apr. 15, 2021, Merck and Ridgeback Biotherapeutics, and Ridgeback Biotherapeutics announced that based on a planned interim…
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
On Apr. 15, 2021, the World Health Organization (WHO) reported that the world was still failing to develop…
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…